Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical Asia Pacific Manufacturing

Turkey Eyed By Sanofi Subsidiary As Potential Generics Hub

This article was originally published in PharmAsia News

Executive Summary

Turkey is seen by at least one major European drug maker as a potential hub for global production of generic drugs.

Turkey is seen by at least one major European drug maker as a potential hub for global production of generic drugs. A senior VP of Zentiva, a Czech generics unit of Sanofi, said the subsidiary plans to use its plant in Turkey as the center of its global production, drawing in part on the quality certification it has already received from 13 nations. Zentiva markets 51 Turkey-produced drugs in 34 countries along with 70% of Sanofi’s products. (Click here for more)

“Czech Firm Sees Turkey As Generic Drugs Hub” – Hurriyet Daily News (Turkey) (7/31/2012)

Table

View full table

Topics

Related Companies

Tags:
BioPharmaceutical Asia Pacific Manufacturing
Latest Headlines

Xaira Launches With $1bn-Plus And End-To-End AI Strategy

Biogen Sees Improving Momentum In Slow Leqembi Launch

Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative

Day One Springs Into Commercial Action With Ojemda Approval

See All
UsernamePublicRestriction

Register

SC081786

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By